Kodiak Sciences Management
Management criteria checks 4/4
Kodiak Sciences' CEO is Victor Perlroth, appointed in Jun 2009, has a tenure of 15.58 years. total yearly compensation is $2.73M, comprised of 26.4% salary and 73.6% bonuses, including company stock and options. directly owns 5.02% of the company’s shares, worth $22.71M. The average tenure of the management team and the board of directors is 3.5 years and 6.6 years respectively.
Key information
Victor Perlroth
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 26.4% |
| CEO tenure | 15.6yrs |
| CEO ownership | 5.0% |
| Management average tenure | 3.5yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Dec 13
Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)
Nov 15We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Aug 02We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Apr 17We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Dec 29We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Sep 09Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?
May 26We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Jan 04Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Sep 25GreenWood Investors - Kodiak Sciences: The Busted Biotech World
Aug 25Kodiak Sciences FQ1 2022 Earnings Preview
Aug 07Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?
May 18Kodiak Sciences: Potential For Comeback After Trial Setback
May 17Kodiak Sciences: KSI-301 Disappoints
Feb 25Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter
Feb 15We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely
Jan 24Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Oct 11Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company
Jul 19Kodiak Sciences EPS in-line
May 10Kodiak Sciences hits the capital raise button; shares dip after hours
Nov 16Kodiak Sciences EPS misses by $0.12
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$192m |
| Jun 30 2024 | n/a | n/a | -US$198m |
| Mar 31 2024 | n/a | n/a | -US$233m |
| Dec 31 2023 | US$3m | US$721k | -US$260m |
| Sep 30 2023 | n/a | n/a | -US$271m |
| Jun 30 2023 | n/a | n/a | -US$298m |
| Mar 31 2023 | n/a | n/a | -US$309m |
| Dec 31 2022 | US$3m | US$691k | -US$334m |
| Sep 30 2022 | n/a | n/a | -US$357m |
| Jun 30 2022 | n/a | n/a | -US$347m |
| Mar 31 2022 | n/a | n/a | -US$312m |
| Dec 31 2021 | US$113m | US$655k | -US$267m |
| Sep 30 2021 | n/a | n/a | -US$220m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$159m |
| Dec 31 2020 | US$9m | US$591k | -US$133m |
| Sep 30 2020 | n/a | n/a | -US$102m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$64m |
| Dec 31 2019 | US$18m | US$526k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$41m |
| Dec 31 2018 | US$6m | US$428k | -US$41m |
Compensation vs Market: Victor's total compensation ($USD2.73M) is about average for companies of similar size in the US market ($USD2.14M).
Compensation vs Earnings: Victor's compensation has been consistent with company performance over the past year.
CEO
Victor Perlroth (51 yo)
15.6yrs
Tenure
US$2,725,068
Compensation
Dr. Victor Perlroth, M.D co-founded Kodiak Sciences Inc. in 2009 and serves as its co-founder, Chairman, President and Chief Executive Officer. Dr. Perlroth serves as Chief Executive officer since June 200...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.6yrs | US$2.73m | 5.02% $ 22.7m | |
| Executive VP | 10.6yrs | US$1.68m | 0.35% $ 1.6m | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Senior Vice President of Development | 7.3yrs | US$321.91k | no data | |
| Senior Vice President of Chemical Development & Manufacturing | 2yrs | no data | no data | |
| Chief Quality Officer | 5yrs | no data | no data | |
| Chief Medical Officer | 2yrs | no data | no data | |
| VP & Corporate Controller | 2yrs | no data | no data |
3.5yrs
Average Tenure
52yo
Average Age
Experienced Management: KOD's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 15.6yrs | US$2.73m | 5.02% $ 22.7m | |
| Lead Independent Director | 6.6yrs | US$248.40k | 0.019% $ 86.2k | |
| Independent Director | 9.3yrs | US$161.90k | 0% $ 0 | |
| Independent Director | 6.6yrs | US$211.90k | 0.0019% $ 8.6k | |
| Independent Director | 6.6yrs | US$216.90k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$239.40k | 0.049% $ 223.7k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
6.6yrs
Average Tenure
60yo
Average Age
Experienced Board: KOD's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 04:30 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kodiak Sciences Inc. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Anita Dushyanth | Berenberg |
| Matthew Luchini | BMO Capital Markets Equity Research |